ErbB2 status and the benefit from two or five years of adjuvant tamoxifen in postmenopausal early stage breast cancer

Annals of Oncology

Volumn 11, Issue 12, 2000, Pages 1545-1550

  Stal O ^a   Borg, A ^b   Ferno M ^b   Kallstrom A C ^a   Malmstrom P ^b   Nordenskjold B ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Breast cancer; ErbB2; HER 2 neu; Tamoxifen; Therapy resistance

Indexed keywords

DNA; ESTROGEN RECEPTOR; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME IMMUNOASSAY; FEMALE; GENE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DNA, NEOPLASM; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, ERBB-2; GENETIC MARKERS; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POSTMENOPAUSE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK ASSESSMENT; TAMOXIFEN;

EID: 0034487507     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008313310474     Document Type: Article

References (43)

1. Tamoxifen for early breast cancer: An overview of the randomised trials
2. Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer
3. Drug resistance to tamoxifen during breast cancer therapy
4. Estrogen receptor mutations in tamoxifen-resistant breast cancer
5. Specific mutations in the estrogen receptor change the properties of antiestrogens to full agonists
6. Multiple splicing variants of the estrogen receptor cDNA are present in human breast tumors
7. c-erbB2 expression predicts tamoxifen efficacy in breast cancer patients
8. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu
9. MCF-7 breast cancer cells overexpressing transfected c-erbB2 have an in vitro growth advantage in estrogen-depleted conditions and a reduced estrogen-dependence and tamoxifen-sensitivity in vivo
10. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells
11. Neuregulins and their receptors: A versatile signaling module in organogenesis and oncogenesis
12. Epidermal growth factor receptor as a marker for poor prognosis in node-negative patients: Neu and tamoxifen failure
13. Relationship between c-erbB2 protein product expression and response to endocrine therapy in advanced breast cancer
14. Oncogene amplification and prognosis in breast cancer: Relationship with systemic treatment
15. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: A Southwest Oncology Group study
16. c-erbB2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases
17. HER-2/neu amplification predicts poor survival in node-positive breast cancer
18. Simultaneous analysis of c-erbB2 expression and DNA content in breast cancer using flow cytometry
19. c-erbB2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer
20. Overexpression of c-erbB2 protein and locoregional recurrence in node-positive breast cancer
21. Nonparametric estimation from incomplete observations
22. Regression models and life tables
23. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
24. HER-2/neu oncogene protein and prognosis in breast cancer
25. HER-2/neu expression in node-negative breast cancer: Direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease
26. The prognostic value of c-erbB2 in primary breast carcinomas: A study on 942 cases
27. neu/erbB2 amplification identifies a poor-prognosis group of women with node-negative breast cancer
28. ErbB2 oncogene in human breast cancer and its clinical significance
29. Prognostic importance of c-erbB2 expression in breast cancer
30. Prognostic significance of HER-2/neu onco-protein expression in node-positive breast cancer
31. c-erbB2 expression and response to adjuvant therapy in women with node-negative early breast cancer
32. ErbB2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer
33. Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein
34. Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer
35. ErbB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer
36. Lack of interaction of tamoxifen use and erbB2/HER-2/neu expression in CALGB 8541. A randomized adjuvant trial of three different doses of cyclophosphamide, doxorubicin and fluorouracil (CAF) in node-positive primary breast cancer
37. The erbB2/HER2 oncogenic receptor of adenocarcinomas: From orphanhood to multiple stromal ligands
38. Relation of oestradiol-mediated growth stimulation with the expression of c-erbB2 protein in xenotransplanted oestradiol-receptor-positive and -negative breast carcinomas
39. Cofactor competition between the ligand-bound oestrogen receptor and an intron 1 enhancer leads to oestrogen repression of erbB2 expression in breast cancer
40. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase
41. Enhanced anti-proliferative activity of the combination of tamoxifen plus HER-2-neu antibody
42. Suppression of transforming growth factor-beta-induced apoptosis through a phosphatidylinositol 3-kinase/Akt-dependent pathway
43. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185(HER2/neu) monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment